{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T11:00:59Z","timestamp":1766401259227,"version":"3.37.3"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007210","name":"RWTH Aachen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007210","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Anaesthesiologie"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In patients with severe hemophilia\u00a0A prolonged bleeding may occur even in cases of minor trauma or surgery.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To investigate the feasibility and efficacy of a recombinant extended half-life (EHL) FVIII concentrate for perioperative bleeding management in a patient with severe hemophilia\u00a0A undergoing liver transplantation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material and methods<\/jats:title>\n                <jats:p>Prior to transplantation FVIII activity and perioperatively required FVIII supply were estimated. In an individualized approach efmoroctocog alfa was supplemented if the intrinsic clotting time in the thrombelastometry was &gt; 170\u202fs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The patient perioperatively received a total of\u00a028,000 IU efmoroctocog alfa. No signs of hemorrhage or complications were detected and no further intervention was necessary.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The present case demonstrates that the use of an EHL FVIII is suitable for a successful perioperative bleeding control even in hemophilia patients at a high bleeding risk during major surgery. Due to the EHL constant FVIII levels could be achieved with relatively few injections. In order to confirm the obtained results, more real-world data in different operative settings are essential. Further research is needed on the use of thrombelastometry to guide substitution of factor VIII perioperatively.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00101-023-01320-1","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T21:02:01Z","timestamp":1691701321000},"page":"883-886","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bleeding management: rFVIIIFc in hemophilia A and liver transplantation","Blutungsmanagement: rFVIIIFc bei H\u00e4mophilie\u00a0A und Lebertransplantation"],"prefix":"10.1007","volume":"72","author":[{"given":"Oliver","family":"Grottke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Rieg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Ulmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Hein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"key":"1320_CR1","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/bja\/aex122","volume":"119","author":"TM Dotsch","year":"2017","unstructured":"Dotsch\u00a0TM, Dirkmann\u00a0D, Bezinover\u00a0D et\u00a0al (2017) Assessment of standard laboratory tests and rotational thromboelastometry for the prediction of postoperative bleeding in liver transplantation. Br J Anaesth 119:402\u2013410","journal-title":"Br J Anaesth"},{"key":"1320_CR2","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1111\/hae.13557","volume":"24","author":"ICL Kremer Hovinga","year":"2018","unstructured":"Kremer Hovinga\u00a0ICL, Schutgens\u00a0REG, Van Der Valk\u00a0PR et al (2018) Continuous infusion of extended half-life factor VIII (efmoroctocog alpha) for surgery in severe haemophilia A. Hemophilia 24:e280\u2013e283","journal-title":"Hemophilia"},{"key":"1320_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","volume":"123","author":"J Mahlangu","year":"2014","unstructured":"Mahlangu\u00a0J, Powell\u00a0JS, Ragni\u00a0MV et\u00a0al (2014) Phase\u00a03\u00a0study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 123:317\u2013325","journal-title":"Blood"},{"key":"1320_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1160\/TH15-10-0780","volume":"116","author":"JN Mahlangu","year":"2016","unstructured":"Mahlangu\u00a0JN, Ragni\u00a0M, Gupta\u00a0N et al (2016) Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thromb Haemost 116:1\u20138","journal-title":"Thromb Haemost"},{"key":"1320_CR5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","volume":"19","author":"A Srivastava","year":"2013","unstructured":"Srivastava\u00a0A, Brewer\u00a0AK, Mauser-Bunschoten\u00a0EP et al (2013) Guidelines for the management of hemophilia. Hemophilia 19:e1\u2013e47","journal-title":"Hemophilia"},{"key":"1320_CR6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/lt.24341","volume":"22","author":"J Togashi","year":"2016","unstructured":"Togashi\u00a0J, Akamatsu\u00a0N, Tanaka\u00a0T et\u00a0al (2016) Living donor liver transplantation for hemophilia with special reference to the management of perioperative clotting factor replacement. Liver Transpl 22:366\u2013370","journal-title":"Liver Transpl"},{"key":"1320_CR7","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1046\/j.1365-2141.2002.03528.x","volume":"117","author":"J Wilde","year":"2002","unstructured":"Wilde\u00a0J, Teixeira\u00a0P, Bramhall\u00a0SR et\u00a0al (2002) Liver transplantation in haemophilia. Br J Haematol 117:952\u2013956","journal-title":"Br J Haematol"}],"container-title":["Die Anaesthesiologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00101-023-01320-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00101-023-01320-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00101-023-01320-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T13:03:19Z","timestamp":1701435799000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00101-023-01320-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":7,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1320"],"URL":"https:\/\/doi.org\/10.1007\/s00101-023-01320-1","relation":{},"ISSN":["2731-6858","2731-6866"],"issn-type":[{"type":"print","value":"2731-6858"},{"type":"electronic","value":"2731-6866"}],"subject":[],"published":{"date-parts":[[2023,8,10]]},"assertion":[{"value":"29 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"O.\u00a0Grottke has received research funding from Bayer HealthCare, Biotest, Boehringer Ingelheim, CSL Behring, Novo Nordisk, Nycomed, Portola, and Octapharma. He has also received honoraria for lectures and consultancy support from Bayer HealthCare, Boehringer Ingelheim, CSL Behring, Octapharma, Pfizer, Portola, Sanofi, and Shire. A.\u00a0Rieg, F.\u00a0Ulmer and M.\u00a0Hein declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. Written informed consent was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The supplement containing this article is not sponsored by industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}